vibegron [extracellular region]

Stable Identifier
Locations in the PathwayBrowser
for Species:
Literature References
PubMed ID Title Journal Year
29366513 Vibegron, a Novel Potent and Selective β3-Adrenoreceptor Agonist, for the Treatment of Patients with Overactive Bladder: A Randomized, Double-blind, Placebo-controlled Phase 3 Study

Yoshida, M, Takeda, M, Gotoh, M, Nagai, S, Kurose, T

Eur. Urol. 2018
26709102 Discovery of Vibegron: A Potent and Selective β3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder

Edmondson, SD, Zhu, C, Kar, NF, Di Salvo, J, Nagabukuro, H, Sacre-Salem, B, Dingley, K, Berger, R, Goble, SD, Morriello, G, Harper, B, Moyes, CR, Shen, DM, Wang, L, Ball, R, Fitzmaurice, A, Frenkl, T, Gichuru, LN, Ha, S, Hurley, AL, Jochnowitz, N, Levorse, D, Mistry, S, Miller, RR, Ormes, J, Salituro, GM, Sanfiz, A, Stevenson, AS, Villa, K, Zamlynny, B, Green, S, Struthers, M, Weber, AE

J. Med. Chem. 2016
29752752 Long-term safety and efficacy of the novel β3 -adrenoreceptor agonist vibegron in Japanese patients with overactive bladder: A phase III prospective study

Yoshida, M, Kakizaki, H, Takahashi, S, Nagai, S, Kurose, T

Int. J. Urol. 2018
External Reference Information
External Reference
Name Identifier Synonyms
bladder disease DOID:365 Urinary Bladder Disease
Cross References
Cite Us!